Invivyd is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious disease. Co. is developing its primary product candidate, adintrevimab, for the prevention and treatment of coronavirus disease 2019 (COVID-19), the disease caused by the virus SARS-CoV-2 and its variants. Adintrevimab is designed to be a neutralizing antibody for both the prevention and treatment of COVID-19. Co. is also evaluating additional neutralizing antibodies targeting the receptor binding domain, as well as other subdomains within the spike protein for COVID-19. The IVVD stock yearly return is shown above.
The yearly return on the IVVD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IVVD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|